

Hojjat Ahmadzadehfar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2583038/publications.pdf>

Version: 2024-02-01

147
papers

6,358
citations

61857

43
h-index

74018

75
g-index

153
all docs

153
docs citations

153
times ranked

5043
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies. <i>Cancers</i> , 2022, 14, 1779.	1.7	7
2	Radioembolization, Principles and indications. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 262-272.	0.3	4
3	Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [⁶⁴ Cu]Cu-DOTA-TOC. <i>Cancers</i> , 2022, 14, 1914.	1.7	3
4	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [¹⁷⁷ Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	3.3	72
5	Theranostic Advances in Breast Cancer in Nuclear Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4597.	1.8	38
6	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [¹⁷⁷ Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076.	3.3	20
7	Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action. <i>Molecular Imaging and Radionuclide Therapy</i> , 2021, 30, 107-109.	0.3	3
8	Theranostics in Brain Tumors. <i>PET Clinics</i> , 2021, 16, 397-418.	1.5	9
9	Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders. <i>PET Clinics</i> , 2021, 16, 429-440.	1.5	2
10	Feasibility and Therapeutic Potential of ¹⁷⁷ Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers. <i>Clinical Nuclear Medicine</i> , 2021, 46, e523-e530.	0.7	68
11	An Impressive Approach in Nuclear Medicine. <i>PET Clinics</i> , 2021, 16, 327-340.	1.5	16
12	PET in the Era of Theranostics. <i>PET Clinics</i> , 2021, 16, xv-xvi.	1.5	0
13	Correspondence. <i>Deutsches A&#x0308;rzteblatt International</i> , 2021, 118 processed the file. I'm wa, 603.	0.6	0
14	Combination Therapies with PRRT. <i>Pharmaceuticals</i> , 2021, 14, 1005.	1.7	8
15	Re: Medical Event: Accidental Oral Administration of ¹⁷⁷ Lu-PSMA to a Patient With Hyperthyroidism. <i>Clinical Nuclear Medicine</i> , 2021, 46, 856-856.	0.7	0
16	Assessment of early oxidative stress following the use of radiotheranostics agents ¹⁷⁷ Lu-PSMA for prostate cancer and ¹⁷⁷ Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C. <i>Nuclear Medicine Communications</i> , 2021, 42, 325-331.	0.5	3
17	Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. <i>European Urology</i> , 2020, 77, 418-419.	0.9	7
18	The value of tumor markers in men with metastatic prostate cancer undergoing [¹⁷⁷ Lu]Lu-PSMA therapy. <i>Prostate</i> , 2020, 80, 17-27.	1.2	27

#	ARTICLE	IF	CITATIONS
19	PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 98-109.	2.5	37
20	An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1015-1016.	3.3	13
21	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for ¹⁸ F-FDG Imaging of PSMA-Suppressed Tumors. <i>Journal of Nuclear Medicine</i> , 2020, 61, 904-910.	2.8	52
22	Application of [68Ga]PSMA PET/CT in Diagnosis and Management of Prostate Cancer Patients. <i>Molecular Imaging and Biology</i> , 2020, 22, 1062-1069.	1.3	10
23	Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. <i>Nuklearmedizin - Nuclear Medicine</i> , 2020, 59, 409-414.	0.3	9
24	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1057-1062.	0.6	15
25	Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3679.	1.0	13
26	Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl ₂ therapy. <i>Medicine (United States)</i> , 2020, 99, e22287.	0.4	7
27	Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-9.	0.6	2
28	Bench-to-Bedside Theranostics in Nuclear Medicine. <i>Current Pharmaceutical Design</i> , 2020, 26, 3804-3811.	0.9	8
29	Precision Medicine Approach in Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 3783-3798.	0.9	9
30	Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 15-20.	0.3	17
31	An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 260.	0.3	6
32	Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2270-2279.	3.3	52
33	Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. <i>Oncotarget</i> , 2019, 10, 4149-4160.	0.8	31
34	Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2252-2259.	3.3	20
35	Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2019.02.028 . <i>European Urology</i> , 2019, 76, e126-e127.	0.9	0
36	Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2019, 322, 237-248.	0.7	14

#	ARTICLE	IF	CITATIONS
37	68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1054-1062.	3.3	51
38	Clinical use of 99mTc-HMPAO-labeled platelets in cerebral sinus thrombosis imaging. <i>Acta Neurologica Belgica</i> , 2019, 119, 549-553.	0.5	2
39	Radionuclide intake risks in the clinical administration of ²²³ RaCl ₂ . <i>Journal of Radiological Protection</i> , 2019, 39, 387-398.	0.6	4
40	177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation. <i>Clinical Nuclear Medicine</i> , 2019, 44, 978-980.	0.7	18
41	Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2019, 44, e329-e335.	0.7	47
42	Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1073-1080.	3.3	57
43	Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. <i>EJNMMI Research</i> , 2019, 9, 102.	1.1	20
44	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	1.6	114
45	177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 406-408.	0.3	12
46	Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 258.	0.3	21
47	[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 323-330.	0.7	22
48	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1721-1730.	3.3	18
49	Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 486-491.	0.7	24
50	Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing ¹⁷⁷ Lu-PSMA Therapy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1033-1034.	2.8	12
51	Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1076-1077.	3.3	63
52	Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 447-455.	1.1	41
53	Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 38-46.	3.3	32
54	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. <i>Journal of Urology</i> , 2018, 199, 370-377.	0.2	71

#	ARTICLE	IF	CITATIONS
55	177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 513-514.	3.3	7
56	Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 243-246.	3.3	65
57	Cancer frequency detected by positron emission tomography-computed tomography in limbic encephalitis. Epilepsy and Behavior, 2018, 89, 105-111.	0.9	5
58	Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction. Oncotarget, 2018, 9, 33312-33321.	0.8	32
59	Radionuclide Therapy for Bone Metastases. PET Clinics, 2018, 13, 491-503.	1.5	16
60	BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy. Clinical Nuclear Medicine, 2018, 43, 609-610.	0.7	9
61	The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. Clinical Cancer Research, 2018, 24, 4672-4679.	3.2	51
62	[177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. Lancet Oncology, The, 2018, 19, e371.	5.1	7
63	Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. Radiation Oncology, 2018, 13, 98.	1.2	19
64	Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma. Current Radiopharmaceuticals, 2018, 11, 14-21.	0.3	40
65	It is time to move forward into the era of Theranostics. EJNMMI Research, 2018, 8, 9.	1.1	13
66	PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 2018, 17, 153601211877606.	0.7	150
67	Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1207-1214.	3.3	55
68	Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1448-1454.	3.3	138
69	The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1473-1479.	3.3	104
70	Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, 704-706.	0.7	22
71	Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel. European Radiology, 2017, 27, 4923-4930.	2.3	8
72	German Multicenter Study Investigating ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 85-90.	2.8	646

#	ARTICLE	IF	CITATIONS
73	Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷ Lu-PSMA-617. Journal of Nuclear Medicine, 2017, 58, 312-319.	2.8	103
74	⁶⁸ Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with ²²³ Ra: Proof of Concept. Journal of Nuclear Medicine, 2017, 58, 438-444.	2.8	54
75	¹⁷⁷ Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 166-167.	3.3	7
76	Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between ^{99m} Tc-Bone-Scintigraphy and [⁶⁸ Ga]Ga-PSMA PET/CT. Pharmaceuticals, 2017, 10, 68.	1.7	47
77	Theranostics in nuclear medicine practice. OncoTargets and Therapy, 2017, Volume 10, 4821-4828.	1.0	161
78	Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience. OncoTargets and Therapy, 2017, Volume 10, 4773-4785.	1.0	9
79	Possible Treatment Approach to an Extravasation of ¹⁷⁷ Lu-PSMA-617. Clinical Nuclear Medicine, 2017, 42, 639-640.	0.7	13
80	Safety and efficacy of ¹⁷⁷ Lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	0.8	2
81	Radioligand therapy of metastatic prostate cancer using ¹⁷⁷ Lu-PSMA-617 after radiation exposure to ²²³ Ra-dichloride. Oncotarget, 2017, 8, 55567-55574.	0.8	59
82	Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget, 2017, 8, 55094-55103.	0.8	66
83	Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy. Oncotarget, 2017, 8, 103108-103116.	0.8	67
84	Diagnostic accuracy of [^{99m} Tc]Tc-Sestamibi in the assessment of thyroid nodules. Oncotarget, 2017, 8, 94681-94691.	0.8	9
85	[¹⁸ F]Fluorodeoxyglucose positron emission tomography reveals a complete remission of refractory metastatic melanoma after therapy with ipilimumab. Indian Journal of Nuclear Medicine, 2017, 32, 66.	0.1	1
86	The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases. OncoTargets and Therapy, 2016, Volume 9, 4089-4098.	1.0	10
87	Targeted Therapy for Metastatic Prostate Cancer with Radionuclides. , 2016, , .		5
88	Therapeutic response and side effects of repeated radioligand therapy with ¹⁷⁷ Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget, 2016, 7, 12477-12488.	0.8	226
89	Positive Influence of ¹⁷⁷ Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, 478-480.	0.7	19
90	Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With ¹⁷⁷ Lu-PSMA-617. Clinical Nuclear Medicine, 2016, 41, 572-573.	0.7	13

#	ARTICLE	IF	CITATIONS
91	68Ga-Labeled Anti-PSMA Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 423-425.	0.7	10
92	68Ga-PSMA-11 PET Represents the Tumorcidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 695-696.	0.7	14
93	Letter To The Editor. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1939-1940.	0.2	1
94	Response and Tolerability of a Single Dose of ¹⁷⁷ Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1334-1338.	2.8	178
95	Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Prediction of Early Arterial Blood Flow Stasis in Radioembolization of Breast Cancer Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1320-1328.	0.2	10
96	Radioligand therapy with ¹⁷⁷ Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. <i>Nuclear Medicine and Biology</i> , 2016, 43, 835.	0.3	13
97	Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases: A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1305-1315.	0.2	42
98	Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With ¹⁷⁷ Lu-PSMA-617. <i>Clinical Nuclear Medicine</i> , 2016, 41, 894-895.	0.7	5
99	Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis. <i>Clinical Nuclear Medicine</i> , 2016, 41, 977-979.	0.7	4
100	Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis. <i>European Radiology</i> , 2016, 26, 2779-2789.	2.3	18
101	Significance of multiple nodal basin drainage in patients with truncal melanoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 60, 274-9.	0.4	3
102	Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. <i>EJNMMI Research</i> , 2015, 5, 54.	1.1	29
103	Volumetric and scintigraphic changes following endoscopic lung volume reduction. <i>European Respiratory Journal</i> , 2015, 45, 262-265.	3.1	8
104	Early side effects and first results of radioligand therapy with ¹⁷⁷ Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. <i>EJNMMI Research</i> , 2015, 5, 114.	1.1	250
105	Effect of Endobronchial Valve Therapy on Pulmonary Perfusion and Ventilation Distribution. <i>PLoS ONE</i> , 2015, 10, e0118976.	1.1	20
106	The role of SPECT/CT in radioembolization of liver tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 115-124.	3.3	38
107	Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 231-237.	3.3	22
108	Outcome and toxicity of salvage therapy with ¹⁷⁷ Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 205-210.	3.3	87

#	ARTICLE	IF	CITATIONS
109	Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. <i>European Radiology</i> , 2014, 24, 267-276.	2.3	26
110	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 505-510.	3.3	76
111	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	1.5	34
112	Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. <i>Journal of Nuclear Medicine</i> , 2014, 55, 183-190.	2.8	158
113	Radioembolization With ⁹⁰ Y Resin Microspheres for HCC Patients With Extensive Tumor Thrombosis Into the Extrahepatic Vessels. <i>Clinical Nuclear Medicine</i> , 2014, 39, 305-307.	0.7	0
114	Appearance of Extraosseous Pelvic Ewing Sarcoma on Triphasic Bone Scan. <i>Clinical Nuclear Medicine</i> , 2014, 39, 406-408.	0.7	2
115	Therapy Planning with SPECT/CT in Radioembolisation of Liver Tumours. , 2014, , 255-270.		0
116	Hepatic volume changes induced by radioembolization with ⁹⁰ Y resin microspheres. A single-centre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 80-90.	3.3	44
117	Long-Term Outcome and Toxicity After Dose-Intensified Treatment with ¹³¹ I-MIBG for Advanced Metastatic Carcinoid Tumors. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2032-2038.	2.8	25
118	Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1857-1861.	2.8	128
119	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 753-761.	1.8	82
120	Neoadjuvant Downsizing by Internal Radiation. <i>Clinical Nuclear Medicine</i> , 2012, 37, 102-104.	0.7	30
121	The Importance of Tc-MAA SPECT/CT for Therapy Planning of Radioembolization in a Patient Treated With Bevacizumab. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1129-1130.	0.7	13
122	⁹⁰ Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1663-1669.	2.8	62
123	Hypertrophy of the contralateral hepatic lobe after selective internal radiation therapy. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 44-45.	2.2	1
124	Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00) Tj ETQq0 0 0 rgBT /Overlock 10 Tf <i>Imaging</i> , 2012, 39, 581-588.	3.3	16
125	Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1316-1325.	3.3	8
126	The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 309-315.	3.3	52

#	ARTICLE	IF	CITATIONS
127	Factors predicting outcome of G1/2ÂGEP NET after PRRT with Lu177-octreotate.. Journal of Clinical Oncology, 2012, 30, e14565-e14565.	0.8	1
128	Myocardial Perfusion Scintigraphy with 99mTc-MIBI. , 2012, , 65-85.		0
129	Iodine-131-Lipiodol therapy in hepatic tumours. Methods, 2011, 55, 246-252.	1.9	21
130	Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 459-466.	3.3	84
131	99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1281-1288.	3.3	20
132	Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1477-1484.	3.3	31
133	Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report. Radiation Oncology, 2011, 6, 94.	1.2	27
134	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology, 2011, 54, 868-878.	3.6	550
135	Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-Octreotate. Journal of Nuclear Medicine, 2011, 52, 1197-1203.	2.8	59
136	Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. Journal of Nuclear Medicine, 2011, 52, 1063-1067.	2.8	29
137	The Significance of ^{99m} Tc-MAA SPECT/CT Liver Perfusion Imaging in Treatment Planning for ⁹⁰ Y-Microsphere Selective Internal Radiation Treatment. Journal of Nuclear Medicine, 2010, 51, 1206-1212.	2.8	114
138	Radioembolization of Liver Tumors With Yttrium-90 Microspheres. Seminars in Nuclear Medicine, 2010, 40, 105-121.	2.5	160
139	Ultrasound detection of PET/CT negative lymph node metastasis in Cutaneous melanoma. European Journal of Dermatology, 2010, 20, 835-6.	0.3	1
140	Dual-Time F-18 FDG-PET/CT Imaging for Diagnosis of Occult Non-Hodgkin Lymphoma in a Patient With Esophageal Cancer. Clinical Nuclear Medicine, 2009, 34, 168-170.	0.7	8
141	Splenic Infarction Mimicking a Necrotizing Metastasis of Malignant Melanoma on F-18 FDG PET/CT. Clinical Nuclear Medicine, 2008, 33, 571-572.	0.7	7
142	False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer, 2007, 58, 418-421.	0.9	51
143	Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine, 2006, 47, 223-33.	2.8	57
144	Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma. , 0, , .		1

#	ARTICLE	IF	CITATIONS
145	Toward radiotheranostics in cancer stem cells: a promising initial step for tumour eradication. Clinical and Translational Imaging, 0, , 1.	1.1	1
146	Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol. , 0, , .		1
147	99m Technetium-HMPAO-labeled platelet scan in practice: Preparation, quality control, and biodistribution studies. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	1